Skip to main content
. Author manuscript; available in PMC: 2018 Aug 15.
Published in final edited form as: Clin Cancer Res. 2017 Apr 26;23(16):4680–4692. doi: 10.1158/1078-0432.CCR-16-3029

Figure 5.

Figure 5

A, CBRC056 PDX tumor sizes after one week of treatment (N = 8). B, CBRC056 PDX tumor sizes after four weeks of treatment. C, CBRC058 PDX tumor sizes after 10 days of treatment (N = 8) with YM155 and perifosine. D, (left) Average CBRC026 tumor sizes in animals treated with PLX4720, cediranib, or both (N = 7–8). Values are shown as mean +/− S.E.M. ranges. (right) CBRC026 PDX tumor sizes after three weeks of treatment. E, (left) Average CBRC026 tumor sizes in animals treated with dasatinib, bortezomib, or both (n = 7–8). Values are shown as mean +/− S.E.M. ranges. (right) CBRC026 PDX tumor sizes after three weeks of treatment.